BioPharmSignal logoBioPharmSignal

Biotech News

Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.Company update

RESEARCH TRIANGLE PARK, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding

Related news

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

MGNXMacroGenics2026-07-02 13:25 EST

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

View all latest news

Fennec Pharmaceuticals Inc.

Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through...

Recent company news

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

FENCFennec Pharmaceuticals Inc.2026-06-15 10:00 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

FENCFennec Pharmaceuticals Inc.2026-06-10 20:30 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-05-21 22:01 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

Stock data

Close
11.29 USD
Market cap
346.68M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States